. 2021 Jun 24;1(3):100037. doi: 10.1016/j.xjidi.2021.100037

Table 1.

Demographic and Clinical Characteristics of the 15 Patients with Sclerotic cGVHD

cGVHD Subjects (n = 15)	Subject ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	Summary¹
Demographics²	Age, y	55	52	40	28	72	59	47	47	71	60	14	65	60	35	70	55 (40–65)
	Race	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	100% C
	Sex	M	M	M	F	M	M	M	F	F	M	M	M	M	M	M	80% M
	BMI	28	24	27	14	31	17	23	34	21	20	22	33	18	23	32	23 (20–31)
Disease characteristics³	Disease histology	AML	MDS	MM	HL	ALL	AML	NHL	ALL	AML	MDS	AML	AML	NHL	ALL	CLL	33% AML 20% ALL 13% NHS 13% MDS 7% MM 7% HL 7% CLL
Transplant characteristics⁴	Transplantation source	BM	PB	PB	PB	PB	PB	PB	BM	PB	PB	PB	PB	PB	PB	—	12/14 PB 2/14 BM
cGVHD characteristics at study entry⁵	NIH score BSA involvement	3	3	2	3	2	3	1	2	1	2	3	1	2	1	—	4/14 NIH 1 5/14 NIH 2 5/14 NIH 3
cGVHD characteristics at study entry⁵	NIH score skin feature	3	3	3	3	3	3	3	3	2	3	3	2	3	3	2	80% NIH 3 20% NIH 2
MyotonPRO session	Days from HCT⁶	1,706	4,604	1,084	1,908	1,169	2,030	2,575	4,429	1,256	1,119	1,339	3,660	1,061	1,686	2,132	1,706 (1,169–2,575)

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; BMI, body mass index; BSA, body surface area; C, Caucasian; cGVHD, chronic graft-versus-host disease; CLL, chronic lymphoblastic leukemia; F, female; HCT, hematopoietic cell transplantation; HL, Hodgkin’s lymphoma; ID, identification; M, male; MDS, myelodysplastic disorder; MM, multiple myeloma; NHL, non–Hodgkin’s lymphoma; NIH, National Institutes of Health; PB, peripheral blood.

Values are shown as median (interquartile range) for continuous variables and n (%) for categorical variables.

Demographics: C, M, and F.

Disease characteristics: AML, ALL, CLL, MDS, MM, NHL, and HL.

⁴

Transplant characteristics: PB and BM.

⁵

NIH Score BSA involvement: 1: 1–18%, 2: 19–50%, and 3: >50%; NIH score skin feature: 2 for superficial sclerosis and 3 for deep sclerosis.

⁶

Days from HCT: days between HCT and MyotonPRO measurement session.